Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
PROM fluctuated 65.6% within 24 hours: price soared from a low of $1.135 to a high of $1.879, then fell back to $1.175

PROM fluctuated 65.6% within 24 hours: price soared from a low of $1.135 to a high of $1.879, then fell back to $1.175

Bitget PulseBitget Pulse2026/05/18 17:30
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, the price of PROM experienced sharp fluctuations, plummeting to a low of $1.135 before surging rapidly to $1.879, with a maximum range of 65.6%. According to the latest data, the price has fallen back to around $1.175. During this period, trading volume increased significantly, with 24-hour turnover on some platforms exceeding $19 million—far surpassing its approximately $22 million market cap—indicating extremely high market participation and clear signs of intense short-term capital trading activity.

Brief Analysis of the Anomaly Cause

- High Trading Volume and Leverage Capital Driven: Trading volume surged within 24 hours, with turnover to market cap ratio exceeding 90% on some platforms, reflecting massive inflows and outflows from short-term capital, easily triggering drastic price swings.

- Predominant Market Speculative Sentiment: There were no official announcements, major whale transfers on-chain, or specific news events directly driving the price; instead, the price action aligns more with typical high-volatility altcoin speculative trading features—similar to previous months' patterns of explosive trading volume and futures liquidation scenarios.

- No Single Leading Factor: The current price anomaly is mainly driven by market liquidity and speculative sentiment in tandem, lacking a verifiable fundamental catalyst.

Market Opinions and Outlook

The overall sentiment among the community and analysts is cautious. Most believe this sharp volatility is a result of short-term speculation, and the price is likely to continue oscillating within the $1.1-$1.8 range. Some forecasts suggest it may test support levels between $1.3-$1.5 in the short term, while also warning that high-leverage positions carry significant drawdown risks. It is recommended to monitor whether trading volume continues to expand as well as the overall trend in the altcoin market.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The Bank of Japan's "hawkish pause" is only awaiting official announcement, with market focus already shifting to December monetary policy signals.

Given that the Bank of Japan just raised interest rates to their highest level in 31 years last month, all respondents predict that the central bank will keep rates unchanged. However, they all also expect the central bank to raise rates in December or January.

智通财经•2026/10/27 02:22
The Bank of Japan's "hawkish pause" is only awaiting official announcement, with market focus already shifting to December monetary policy signals.

Voices of doubt arise, Moderna CEO reassures the market: Personalized cancer vaccines will cover more types of cancer

Moderna's CEO is highly confident about the prospects of the personalized mRNA cancer vaccine intismeran autogene, stating that it will play a role in more cancers beyond melanoma and drawing parallels with Merck's blockbuster drug Keytruda. Jefferies warns that cross-indication replication is still inconclusive; Citi maintains a "sell" rating, pointing out that commercial application remains limited, with critical issues such as patient suitability, manufacturing, and overall survival data yet to be addressed.

华尔街见闻•2026/10/27 02:02
Voices of doubt arise, Moderna CEO reassures the market: Personalized cancer vaccines will cover more types of cancer